V9G0 Stock Chart & Stats
€1.43
€0.00(0.00%)
At close: 4:00 PM EDT
€1.43
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.42 - €1.43
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€6.74M
Enterprise Value€14.45
Total Cash (Recent Filing)€11.78M
Total Debt (Recent Filing)€7.29M
Price to Earnings (P/E)―
Beta-0.82
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.29
Shares Outstanding8,589,266
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.07
Price to Sales (P/S)0.05
P/FCF Ratio-0.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt ReductionDebt reduction provides some relief to a stressed capital structure and may lower financing pressure over time. If sustained, it can preserve more resources for operations and strategic investment, although the negative equity position still limits overall financial flexibility.
Strategic Portfolio SimplificationThe planned divestiture could simplify the portfolio, generate proceeds, and support the balance sheet while XWELL refocuses on its remaining wellness operations and stated strategic direction. The transaction is strategically meaningful, though completion depends on approvals and other conditions.
Improved Gross MarginImproved gross profitability indicates that the services retained by XWELL may be generating better economics than at the prior trough. Sustaining that progress could improve operating leverage and support a path toward healthier earnings, though current costs remain too high.
Bears Say
Severe Revenue ContractionSharp and prolonged revenue contraction weakens operating scale and makes fixed costs harder to absorb. The multi-year pattern suggests that restoring a durable growth trajectory is a central challenge, limiting the company’s ability to convert improved gross profitability into sustainable earnings.
Persistent UnprofitabilityDeep operating losses and an approximately negative 83% net margin show that current revenue is not sufficient to cover the company’s cost base. Persistent unprofitability can consume financial resources, constrain investment choices, and make any recovery dependent on substantial operational improvement.
Negative Equity And Cash BurnOngoing cash consumption reduces the funds available to support operations and strategic execution, while negative equity signals a fragile capital structure. Together, these conditions increase reliance on financing or asset transactions and reduce resilience if the turnaround takes longer than expected.
XWELL News
V9G0 FAQ
What was XWELL’s price range in the past 12 months?
XWELL lowest stock price was €1.42 and its highest was €1.43 in the past 12 months.
What is XWELL’s market cap?
XWELL’s market cap is €6.74M.
When is XWELL’s upcoming earnings report date?
XWELL’s upcoming earnings report date is Nov 18, 2026 which is in 57 days.
How were XWELL’s earnings last quarter?
XWELL released its earnings results on Aug 17, 2026. The company reported -€0.23 earnings per share for the quarter.
Is XWELL overvalued?
According to Wall Street analysts XWELL’s price is currently Overvalued.
Does XWELL pay dividends?
XWELL does not currently pay dividends.
What is XWELL’s EPS estimate?
XWELL’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XWELL have?
XWELL has 8,589,266 shares outstanding.
What happened to XWELL’s price movement after its last earnings report?
XWELL reported an EPS of -€0.23 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of XWELL?
Currently, no hedge funds are holding shares in DE:V9G0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
XWELL
XWELL Inc. functions as a health and wellness services provider, primarily operating within airports. The company delivers its diverse offerings through various brands, including XpresSpa, XpresTest, Treat, and HyperPointe. Its core services feature a range of spa treatments such as massages, nail care, and skincare, further complemented by the sale of spa, travel, and general retail merchandise. Beyond relaxation services, XWELL also manages dedicated wellness centers. These facilities provide crucial health diagnostic services, encompassing COVID-19 screening and testing, rapid tests for various communicable diseases like influenza, RSV, and different flu strains (A&B), alongside seasonal flu vaccinations and other medical diagnostic procedures. To enhance accessibility for the traveling public, the company utilizes an integrated digital platform and a tailored retail selection. As of December 31, 2021, XWELL maintained a significant global presence, with 52 spa and clinic locations spanning 24 airports across the United States, the Netherlands, and the United Arab Emirates. The organization, headquartered in New York, New York, underwent a name change in October 2022, transitioning from its former identity as XpresSpa Group, Inc. to its current designation, XWELL Inc.
Technical Analysis
Medifast
―
Regis
―
MEDIROM Healthcare Technologies
―
E-Home Household Service Holdings
―
Interactive Strength Inc
―